0000899243-20-025166.txt : 20200915 0000899243-20-025166.hdr.sgml : 20200915 20200915201040 ACCESSION NUMBER: 0000899243-20-025166 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200911 FILED AS OF DATE: 20200915 DATE AS OF CHANGE: 20200915 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Katkin Keith CENTRAL INDEX KEY: 0001314596 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36620 FILM NUMBER: 201177125 MAIL ADDRESS: STREET 1: C/O UROVANT SCIENCES, INC. STREET 2: 5281 CALIFORNIA AVENUE, SUITE 100 CITY: IRVINE STATE: CA ZIP: 92617 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Novus Therapeutics, Inc. CENTRAL INDEX KEY: 0001404281 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 19900 MACARTHUR BLVD. STREET 2: SUITE 550 CITY: IRVINE STATE: CA ZIP: 92612 BUSINESS PHONE: 949-238-8090 MAIL ADDRESS: STREET 1: 19900 MACARTHUR BLVD. STREET 2: SUITE 550 CITY: IRVINE STATE: CA ZIP: 92612 FORMER COMPANY: FORMER CONFORMED NAME: Tokai Pharmaceuticals Inc DATE OF NAME CHANGE: 20070622 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-09-11 0 0001404281 Novus Therapeutics, Inc. NVUS 0001314596 Katkin Keith C/O NOVUS THERAPEUTICS, INC. 19900 MACARTHUR BLVD., SUITE 550 IRVINE CA 92612 1 0 0 0 Stock Option (Right to Buy) 500.00 2020-09-11 4 A 0 5907.15 0.00 A 2030-09-11 Series X1 Convertible Preferred Stock 5907.15 5907.15 D This option represents a right to purchase a total of 5,907.15 shares of the Issuer's Series X1 Convertible Preferred Stock, which will vest in equal monthly installments over two years, subject to the Reporting Person's continued service to the Issuer through each vesting date. The Reporting Person's ability to exercise the option will be subject to stockholder approval under Nasdaq Marketplace Rule 5635(c). Each share of Series X1 Convertible Preferred Stock will be convertible into 1,000 shares of Common Stock upon receipt of the requisite approval of the stockholders of the Issuer. /s/ Ryan A. Murr, as attorney-in-fact for Keith Katkin 2020-09-15